JW Pharmaceutical Corp (001065) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of JW Pharmaceutical Corp KRW 59,346, price KRW 22,600, upside +162.6%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JW Pharmaceutical Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 19,800 KRW – 54,025 KRW · fair‑value band 40,042 KRW – 80,042 KRW · the 22,600 KRW price screens below the 59,346 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow JW Pharmaceutical in your weekly email
Every Wednesday you see whether JW Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer.
Show more
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.
Stock analysis
JW Pharmaceutical Corp (001065) currently trades at 22,600 KRW, while our model-based Fair Value estimate is 59,346 KRW, implying the stock looks roughly 61.9% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 61,809 KRW per share, and 20 of the 24 models we run sit above the 22,600 KRW price.
Bear case: the Asset-Based group reads lowest at 12,315 KRW, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 40,042 KRW (bear) to 80,042 KRW (bull), the price of 22,600 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
JW Pharmaceutical Corp reported revenue of 775B KRW in FY2025 versus 607B KRW in FY2021, a compound +6.3%/yr. Reported net income was 61.5B KRW in FY2025.
Key figures
Market cap 648B KRW (≈ $483M) · P/S ratio 0.82 · Dividend yield 3.0% · Net margin 7.9% · Return on equity 20.1% · Return on assets (EBIT) 12.0% · Operating margin 16.8% · Revenue (TTM) 790B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 163%, 001065 screens cheaper than that median.
Fair Value models
Bear 40,042 KRWFair Value 59,346 KRWBull 80,042 KRW
Price 22,600 KRW · Upside +162.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2020 (pandemic). Over 10 years: +6.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +17.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.6%
Dividend (yield on the price)3.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 12%
⚠ Rate on operating basis: 2025 sits 71% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −3.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 597 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is JW Pharmaceutical Corp (001065) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 59,346 KRW versus a price of 22,600 KRW, about +163% upside (undervalued).
What is the fair value of 001065?
Our model-based fair value for JW Pharmaceutical Corp is 59,346 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 22,600 KRW.
What is the quality score of 001065?
JW Pharmaceutical Corp has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JW Pharmaceutical Corp (001065)?
Our model-based price target is the fair value of 59,346 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 40,042 KRW, optimistic scenario 80,042 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the JW Pharmaceutical Corp stock forecast for 2026?
Our models put fair value at 59,346 KRW, about +163% upside versus a price of 22,600 KRW (undervalued). Cautious scenario 40,042 KRW, optimistic scenario 80,042 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of JW Pharmaceutical Corp (001065)?
JW Pharmaceutical Corp reported trailing-twelve-month revenue of about 790B KRW (latest available figure, as of Sep 24, 2026).
Does JW Pharmaceutical Corp pay a dividend?
JW Pharmaceutical Corp currently shows a dividend yield of about 2.99% relative to its recent price (as of Sep 24, 2026).
What growth is priced into JW Pharmaceutical Corp (001065)?
For today's price to be fair in a discounted-cash-flow model, JW Pharmaceutical Corp would have to grow free cash flow by -1.8 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 001065 use?
Our models discount JW Pharmaceutical Corp at 11.5 %: a base by market capitalisation (small), damped by beta 0.96, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For JW Pharmaceutical Corp that is -1.8 % per year a year over ten years, using the same discount rate (11.5 %) and the same formula as our fair value.
How much growth has JW Pharmaceutical Corp (001065) delivered so far?
Over the past 5 years revenue at JW Pharmaceutical Corp grew +7.2 % a year. The price currently implies -1.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of JW Pharmaceutical Corp (001065) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into JW Pharmaceutical Corp (-1.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of JW Pharmaceutical Corp (001065)?
The free-cash-flow yield on the price is 11.83 %: that much free cash flow JW Pharmaceutical Corp produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of JW Pharmaceutical Corp (001065)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JW Pharmaceutical Corp it is 59,346 KRW per share (as of Sep 24, 2026), against a price of 22,600 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is JW Pharmaceutical Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 001065 trades below its calculated fair value: price 22,600 KRW, fair value 59,346 KRW, a gap of about +163% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 001065?
No. The price is what the market pays today (22,600 KRW); the fair value is what the company's own numbers justify (59,346 KRW). For JW Pharmaceutical Corp the two are 36,746 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is JW Pharmaceutical Corp worth?
The market values JW Pharmaceutical Corp at about 648B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 22,600 KRW; our models calculate a fair value of 59,346 KRW per share.
What do the bullish and bearish scenarios say about 001065?
Our models span a range for JW Pharmaceutical Corp: cautious scenario 40,042 KRW, base 59,346 KRW, optimistic 80,042 KRW per share (as of Sep 24, 2026, price 22,600 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JW Pharmaceutical Corp (001065)?
Balance-sheet figures for JW Pharmaceutical Corp (as of Sep 24, 2026): return on equity 20.1%, debt of 0.07 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 001065 from its 52-week high?
JW Pharmaceutical Corp trades at 22,600 KRW, about 22% below its 52-week high of 29,091 KRW and 14% above the low of 19,800 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 59,346 KRW is for.
Which stocks are comparable to JW Pharmaceutical Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JW Pharmaceutical Corp stock attractive at the current price?
The data as of Sep 24, 2026: price 22,600 KRW, calculated fair value 59,346 KRW (+163%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 001065 calculated?
We run JW Pharmaceutical Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 59,346 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. JW Pharmaceutical Corp currently trades 62 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JW Pharmaceutical Corp (001065)?
The closing price on Oct 2, 2026 was 22,600 KRW. Our model-based fair value is 59,346 KRW, about +163% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JW Pharmaceutical Corp right now?
The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (40,042 KRW). The market is more pessimistic than our downside scenario. A fairly wide model range (40,042 KRW to 80,042 KRW) leaves room in how you read the outcome.
Key figures of JW Pharmaceutical Corp
How large is the market capitalisation of JW Pharmaceutical Corp (001065)?
The market capitalisation of JW Pharmaceutical Corp is 648B KRW (≈ $483M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JW Pharmaceutical Corp (001065)?
The price-to-sales ratio of JW Pharmaceutical Corp is 0.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of JW Pharmaceutical Corp (001065)?
The dividend yield of JW Pharmaceutical Corp is 3.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of JW Pharmaceutical Corp (001065)?
The net margin of JW Pharmaceutical Corp is 7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JW Pharmaceutical Corp (001065)?
The return on equity (ROE) of JW Pharmaceutical Corp is 20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JW Pharmaceutical Corp (001065)?
On an EBIT basis the return on assets of JW Pharmaceutical Corp is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JW Pharmaceutical Corp (001065)?
The operating margin of JW Pharmaceutical Corp is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JW Pharmaceutical Corp (001065)?
Revenue at JW Pharmaceutical Corp is growing +7.9% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JW Pharmaceutical Corp (001065)?
Earnings per share at JW Pharmaceutical Corp are growing +59.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does JW Pharmaceutical Corp (001065) carry?
The net debt of JW Pharmaceutical Corp is 56.1B KRW (fiscal year 2024, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch JW Pharmaceutical Corp in the live analysis
One click puts JW Pharmaceutical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
